Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Arena Pharmaceuticals (ARNA)

Arena Pharmaceuticals (ARNA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Arena Pharmaceuticals 6154 Nancy Ridge Drive San Diego CA 92121 USA

P: 858-453-7200

Description:

Arena Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing novel drugs that target G protein-coupled receptors, or GPCRs, to address unmet medical needs. BELVIQ (lorcaserin HCl), their internally discovered drug for chronic weight management, is their first and only drug approved by any regulatory agency for marketing. BELVIQ was approved by the US Food and Drug Administration, or FDA, for marketing in the United States, and was made available by prescription in June 2013 to adults who are overweight with a comorbidity or obese. They are exploring BELVIQ for possible new indications, using different formulations, and in combination with other drugs.

Key Statistics

Overview:

Market Capitalization, $K 4,420,142
Shares Outstanding, K 60,335
Annual Sales, $ 320 K
Annual Net Income, $ -404,730 K
Last Quarter Sales, $ 40 K
Last Quarter Net Income, $ -122,160 K
60-Month Beta 0.73
% of Insider Shareholders 3.05%
% of Institutional Shareholders 91.18%
Float, K 58,495
% Float 96.95%

Growth:

1-Year Return 56.07%
3-Year Return 73.31%
5-Year Return 388.40%
5-Year Revenue Growth -99.17%
5-Year Earnings Growth -64.22%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -2.10 on 02/23/21
Next Earnings Date N/A
Earnings Per Share ttm -7.40
EPS Growth vs. Prev Qtr -24.26%
EPS Growth vs. Prev Year -19.32%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00
Most Recent Split 1-10 on 06/19/17

ARNA Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward -16.63
Price/Earnings to Growth N/A
Return-on-Equity % -36.12%
Return-on-Assets % -33.07%
Profit Margin % -126,478.13
Net Margin % -676.30
Debt/Equity 0.04
Price/Sales 14,527.68
Price/Cash Flow N/A
Price/Book 4.31
Book Value/Share 18.58
Interest Coverage -88.54
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar